Company news
Ardelyx, Inc. news in 2022
Ardelyx, Inc.'s news releases, calls and decks from 2022, newest first.
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
December 28, 2022
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
December 15, 2022
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
November 21, 2022
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
November 15, 2022
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
November 15, 2022
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 2, 2022
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on...
November 2, 2022
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
October 30, 2022
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
October 26, 2022
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
October 23, 2022
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
October 19, 2022
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
August 3, 2022
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
August 1, 2022
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
July 27, 2022
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
June 29, 2022
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
June 20, 2022
Ardelyx to Present at the Jefferies 2022 Healthcare Conference
June 2, 2022
Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 23, 2022
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
May 16, 2022
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
May 4, 2022
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
April 27, 2022
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
April 24, 2022
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
April 10, 2022
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
April 6, 2022
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
April 3, 2022
Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference
March 1, 2022
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
February 27, 2022
Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners
February 23, 2022
Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
February 21, 2022